Contact Us
Careers
Press Releases
LinkedIn
About Us
Executive Leadership Team
Board of Directors
Scientific Advisory Board
Medicines
Pipeline
Anaphylm™
Libervant®
Technologies
Services
Our Responsibilities
Investors
Press Releases
Events & Presentations
Corporate Governance
SEC Filings
Stock Information
Analyst Coverage
Quarterly Results
Corporate Fact Sheet
Contact Us
Careers
Press Releases
Linkedin
Meaningful
improvements.
Innovative
delivery.
We're advancing medicines to bring meaningful improvements to patients' lives through innovative science and delivery technologies.
Learn about our pipeline
2.5+ billion doses
and counting
Our PharmFilm® technology is behind trusted, high-quality brands that have simplified treatment regimens and improved patients’ lives
Learn about our medicines
Two breakthrough
technologies.
Endless possibilities.
Our core technologies feature PharmFilm, with a proven track record of transformational drug delivery, and AdrenaVerse—our next frontier of innovation.
Learn about our technologies
Manufacturing
products sold
worldwide
Backed by 20+ years of experience, we manufacture and package trusted products for global brands, all made in the USA.
Learn about services
01.
Pipeline
02.
Medicines
03.
Technologies
04.
Services
Our success is proven
Learn more about us
1
FDA approvals
with products available on six continents
1
+ patents
filed in the U.S. and worldwide
0
+ billion
PharmFilm® doses shipped worldwide
0
+ years
since the company was founded
Learn more about us
Latest News
View all press releases
October 15, 2026
Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027
Read More
October 14, 2026
Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film
Read More
September 29, 2026
Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly
Read More
September 17, 2026
Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film
Read More
September 01, 2026
Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
Read More
August 11, 2026
Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Read More
INVESTOR RELATIONS
Simplified medicine delivery
Our patient-centric approach guides the way
NASDAQ: AQST
3.78
USD
-0.28
(
-6.90
%) Today
Events and presentations
ESG Sustainability Report
Press releases
SEC Filings